Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.

Cardiologist Mary Branch, MD, reveals how depression, meds, and food insecurity shape heart risk—and why cardiology-psychiatry teamwork matters.